ATE475708T1 - Fusionskonstrukte und deren verwendung zur produktion von antikörpern mit erhöhter fc rezeptor bindungsaffinität und effektorfunktion - Google Patents
Fusionskonstrukte und deren verwendung zur produktion von antikörpern mit erhöhter fc rezeptor bindungsaffinität und effektorfunktionInfo
- Publication number
- ATE475708T1 ATE475708T1 AT04704310T AT04704310T ATE475708T1 AT E475708 T1 ATE475708 T1 AT E475708T1 AT 04704310 T AT04704310 T AT 04704310T AT 04704310 T AT04704310 T AT 04704310T AT E475708 T1 ATE475708 T1 AT E475708T1
- Authority
- AT
- Austria
- Prior art keywords
- increased
- receptor binding
- effector function
- antibodies
- fusion constructs
- Prior art date
Links
- 102000009109 Fc receptors Human genes 0.000 title abstract 2
- 108010087819 Fc receptors Proteins 0.000 title abstract 2
- 239000012636 effector Substances 0.000 title abstract 2
- 230000004927 fusion Effects 0.000 title abstract 2
- 230000013595 glycosylation Effects 0.000 abstract 2
- 238000006206 glycosylation reaction Methods 0.000 abstract 2
- 230000003197 catalytic effect Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2477—Hemicellulases not provided in a preceding group
- C12N9/2488—Mannanases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01038—Beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase (2.4.1.38)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01094—Protein N-acetylglucosaminyltransferase (2.4.1.94)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01114—2-Coumarate O-beta-glucosyltransferase (2.4.1.114)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01024—Alpha-mannosidase (3.2.1.24)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01096—Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (3.2.1.96)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01114—Mannosyl-oligosaccharide 1,3-1,6-alpha-mannosidase (3.2.1.114)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/05—Fusion polypeptide containing a localisation/targetting motif containing a GOLGI retention signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01024—1,4-Alpha-glucan 6-alpha-glucosyltransferase (2.4.1.24)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01096—Hexosyltransferases (2.4.1) sn-Glycerol-3-phosphate 1-galactosyltransferase (2.4.1.96)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01144—Beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase (2.4.1.144)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44130703P | 2003-01-22 | 2003-01-22 | |
US49125403P | 2003-07-31 | 2003-07-31 | |
US49514203P | 2003-08-15 | 2003-08-15 | |
PCT/IB2004/000844 WO2004065540A2 (en) | 2003-01-22 | 2004-01-22 | Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE475708T1 true ATE475708T1 (de) | 2010-08-15 |
Family
ID=32777012
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04704310T ATE475708T1 (de) | 2003-01-22 | 2004-01-22 | Fusionskonstrukte und deren verwendung zur produktion von antikörpern mit erhöhter fc rezeptor bindungsaffinität und effektorfunktion |
Country Status (19)
Country | Link |
---|---|
US (2) | US8367374B2 (de) |
EP (4) | EP2264152B1 (de) |
JP (4) | JP5425365B2 (de) |
KR (2) | KR101498588B1 (de) |
CN (1) | CN103540600B (de) |
AT (1) | ATE475708T1 (de) |
AU (2) | AU2004205802B2 (de) |
CA (1) | CA2513797C (de) |
CZ (1) | CZ308720B6 (de) |
DE (1) | DE602004028337D1 (de) |
ES (3) | ES2542885T3 (de) |
HK (1) | HK1089205A1 (de) |
IL (2) | IL169805A (de) |
MX (1) | MXPA05007781A (de) |
NO (1) | NO339270B1 (de) |
NZ (5) | NZ603037A (de) |
PL (7) | PL224786B1 (de) |
SG (2) | SG179292A1 (de) |
WO (1) | WO2004065540A2 (de) |
Families Citing this family (225)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
ATE458007T1 (de) | 1998-04-20 | 2010-03-15 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
JP3528611B2 (ja) * | 1998-07-16 | 2004-05-17 | Jfeスチール株式会社 | 結束材の切断方法及びその装置 |
WO2003011878A2 (en) | 2001-08-03 | 2003-02-13 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
PL224786B1 (pl) | 2003-01-22 | 2017-01-31 | Glycart Biotechnology Ag | Wyizolowany kwas nukleinowy, ssaczy wektor ekspresyjny, komórki gospodarza, fuzja polipeptydowa i sposób jej wytwarzania, sposoby in vitro i ex vivo modyfikowania profilu glikozylacji polipeptydu wytwarzanego przez komórki gospodarza |
EP1614693A4 (de) * | 2003-03-31 | 2006-07-19 | Kirin Brewery | Reinigung eines humanen monoklonalen antikörpers und humanen polyklonalen antikörpers |
SI2380911T1 (en) | 2003-11-05 | 2018-07-31 | Roche Glycart Ag | ANTIGEN-RELATED PATIENTS WITH INCREASED ATTENTION ON THE RECEPTOR FC AND EFFECTORAL FUNCTION |
TW200539855A (en) * | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
US20060045877A1 (en) * | 2004-08-30 | 2006-03-02 | Goldmakher Viktor S | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
AU2006211037B2 (en) | 2005-02-07 | 2012-05-24 | Roche Glycart Ag | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
SG170006A1 (en) * | 2005-02-18 | 2011-04-29 | Medarex Inc | Monoclonal antibodies against cd30 lacking fucosyl residues |
US20060223096A1 (en) * | 2005-03-25 | 2006-10-05 | Glycart Biotechnology Ag | Antigen binding molecules directed to MCSP and having increased Fc receptor binding affinity and effector function |
MX2007013924A (es) * | 2005-05-09 | 2008-01-28 | Glycart Biotechnology Ag | Moleculas que unen antigeno que tienen regiones fc modificadas y union alterada a receptores fc. |
US7566456B2 (en) * | 2005-06-23 | 2009-07-28 | Haiming Chen | Allergen vaccine proteins for the treatment and prevention of allergic diseases |
ES2530265T3 (es) | 2005-07-21 | 2015-02-27 | Genmab A/S | Ensayos de potencia de unión de una sustancia medicamentosa de anticuerpo a un receptor FC |
NO345919B1 (no) | 2005-08-26 | 2021-10-18 | Roche Glycart Ag | Modifiserte antigen-bindende molekyler med endret celle-signaliseringsaktivitet |
EP1996716B1 (de) | 2006-03-20 | 2011-05-11 | The Regents of the University of California | Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting |
WO2008060645A2 (en) * | 2006-03-21 | 2008-05-22 | Genentech, Inc. | Combinatorial therapy involving alpha5beta1 antagonists |
US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
US20100166741A1 (en) * | 2006-07-13 | 2010-07-01 | Genentech , Inc. | Altered br-3 binding polypeptides |
AR062223A1 (es) | 2006-08-09 | 2008-10-22 | Glycart Biotechnology Ag | Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas |
NZ576855A (en) | 2006-10-12 | 2012-08-31 | Forerunner Pharma Res Co Ltd | Diagnosis and treatment of cancer using anti-ereg antibody |
RU2479629C2 (ru) * | 2007-03-07 | 2013-04-20 | Гликофи, Инк. | Продукция гликопротеинов с модифицированным фукозилированием |
EP1995309A1 (de) * | 2007-05-21 | 2008-11-26 | Vivalis | Rekombinante Proteinproduktion in EBx -Vogelzellen |
CA2795379A1 (en) | 2007-06-15 | 2008-12-18 | Centre National De La Recherche Scientifique | Modifying glycoprotein production in plants |
US8940298B2 (en) | 2007-09-04 | 2015-01-27 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection |
MX2010002406A (es) | 2007-09-05 | 2010-04-27 | Hoffmann La Roche | Terapia de combinacion con anticuerpos anti-cd20 de tipo i y de tipo ii. |
PL2195017T3 (pl) | 2007-10-01 | 2015-03-31 | Bristol Myers Squibb Co | Ludzkie antyciała, które wiążą mezotelinę i ich zastosowania |
US20090098118A1 (en) | 2007-10-15 | 2009-04-16 | Thomas Friess | Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
WO2009086072A2 (en) | 2007-12-21 | 2009-07-09 | Genentech, Inc. | Therapy of rituximab-refractory rheumatoid arthritis patients |
DK2242772T3 (en) * | 2007-12-26 | 2015-01-05 | Biotest Ag | Immunoconjugates that targets CD138, and uses thereof |
BRPI0821447A2 (pt) * | 2007-12-26 | 2015-06-16 | Biotest Ag | Anticorpo de alvejamento engenheirado, composição farmacêutica, hibridoma, ensaio com base em anticorpo, polipeptídeo isolado, e, método para ligação homogênea |
JP2011508738A (ja) * | 2007-12-26 | 2011-03-17 | バイオテスト・アクチエンゲゼルシヤフト | Cd138発現腫瘍細胞のターゲティングを向上させる方法及び剤 |
EP2238169A1 (de) * | 2007-12-26 | 2010-10-13 | Biotest AG | Verfahren zur verminderung der zytotoxischen nebenwirkungen und zur erhöhung der wirksamkeit von immunkonjugaten |
AU2009204974A1 (en) * | 2008-01-15 | 2009-07-23 | F. Hoffmann-La Roche Ag | Afucosylated antibodies against CCR5 and their use |
KR101054362B1 (ko) * | 2008-07-03 | 2011-08-05 | 재단법인 목암생명공학연구소 | 재조합 단백질의 푸코스 함량을 감소시키는 방법 |
CA2730668C (en) | 2008-07-18 | 2020-04-28 | Medicago Inc. | New influenza virus immunizing epitope |
WO2010048588A2 (en) * | 2008-10-23 | 2010-04-29 | Massachusetts Institute Of Technology | Directed engagement of activating fc receptors |
ES2712732T3 (es) | 2009-02-17 | 2019-05-14 | Cornell Res Foundation Inc | Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico |
US20100247484A1 (en) | 2009-03-31 | 2010-09-30 | Heinrich Barchet | Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3 |
JP2012518680A (ja) | 2009-03-31 | 2012-08-16 | ロシュ グリクアート アクチェンゲゼルシャフト | ヒト化抗EGFRIgG1抗体及びイリノテカンによる癌の処置 |
KR101431318B1 (ko) | 2009-04-02 | 2014-08-20 | 로슈 글리카트 아게 | 전장 항체 및 단일쇄 fab 단편을 포함하는 다중특이성 항체 |
CA2757531A1 (en) | 2009-04-07 | 2010-10-14 | Roche Glycart Ag | Bispecific anti-erbb-3/anti-c-met antibodies |
JP5612663B2 (ja) | 2009-04-07 | 2014-10-22 | ロシュ グリクアート アクチェンゲゼルシャフト | 二重特異性抗ErbB−1/抗c−Met抗体 |
CA2757931C (en) | 2009-04-07 | 2019-03-26 | Roche Glycart Ag | Trivalent, bispecific antibodies |
NZ613647A (en) * | 2009-05-06 | 2015-02-27 | Biotest Ag | Uses of immunoconjugates targeting cd138 |
JP5719354B2 (ja) | 2009-05-27 | 2015-05-20 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 三重又は四重特異性抗体 |
WO2010137654A1 (ja) | 2009-05-29 | 2010-12-02 | 株式会社未来創薬研究所 | Egfファミリーリガンドのアンタゴニストを成分とする医薬組成物 |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
TWI409079B (zh) | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | 非典型岩藻醣化cd20抗體與苯達莫斯汀(bendamustine)之組合療法 |
NZ597325A (en) | 2009-08-14 | 2014-03-28 | Roche Glycart Ag | Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone |
TWI412375B (zh) | 2009-08-28 | 2013-10-21 | Roche Glycart Ag | 人類化抗cdcp1抗體 |
TW201113037A (en) | 2009-08-28 | 2011-04-16 | Hoffmann La Roche | Antibodies against CDCP1 for the treatment of cancer |
RU2570554C2 (ru) | 2009-08-31 | 2015-12-10 | Роше Гликарт Аг | Гуманизированные моноклональные антитела к сеа с созревшей аффинностью |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
SG179196A1 (en) | 2009-09-16 | 2012-04-27 | Genentech Inc | Coiled coil and/or tether containing protein complexes and uses thereof |
KR101860175B1 (ko) | 2009-10-26 | 2018-05-21 | 에프. 호프만-라 로슈 아게 | 글리코실화된 면역글로불린의 제조 방법 |
CN102753194B (zh) | 2009-12-02 | 2015-07-08 | 伊麦吉纳博公司 | 靶向人前列腺特异性膜抗原的j591微抗体和双抗体 |
HUE029026T2 (en) | 2009-12-22 | 2017-01-30 | Roche Glycart Ag | Anti-HER3 antibodies and their applications |
CN102686241A (zh) | 2009-12-29 | 2012-09-19 | 霍夫曼-拉罗奇有限公司 | 抗体配制剂 |
TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
CN102844049B (zh) | 2010-04-27 | 2016-06-01 | 罗切格利卡特公司 | 无岩藻糖基化CD20抗体与mTOR抑制剂的联合疗法 |
US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
WO2012010582A1 (en) | 2010-07-21 | 2012-01-26 | Roche Glycart Ag | Anti-cxcr5 antibodies and methods of use |
BR112013002535A2 (pt) | 2010-08-03 | 2019-09-24 | Hoffmann La Roche | biomarcadores de leucemia linfocítica crônica (cll) |
PT2603530T (pt) | 2010-08-13 | 2018-01-09 | Roche Glycart Ag | Anticorpos anti-fap e métodos de utilização |
WO2012020038A1 (en) | 2010-08-13 | 2012-02-16 | Roche Glycart Ag | Anti-tenascin-c a2 antibodies and methods of use |
AR082693A1 (es) | 2010-08-17 | 2012-12-26 | Roche Glycart Ag | Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf |
WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
CA2819436A1 (en) | 2010-12-16 | 2012-06-21 | Roche Glycart Ag | Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor |
WO2012085111A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
JPWO2012105699A1 (ja) * | 2011-02-03 | 2014-07-03 | 株式会社イーベック | 補体依存性生物活性の高い抗体の産生法 |
SI3489255T1 (sl) | 2011-02-10 | 2021-11-30 | Roche Glycart Ag | Mutantni polipeptidi interlevkina-2 |
US20120258073A1 (en) | 2011-02-10 | 2012-10-11 | Christian Gerdes | Immunotherapy |
CA2824824A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Monovalent antigen binding proteins |
JP5764677B2 (ja) | 2011-02-28 | 2015-08-19 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 抗原結合タンパク質 |
DK2681244T3 (da) * | 2011-03-02 | 2018-01-29 | Roche Glycart Ag | Cea-antistoffer |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
DK2714738T3 (en) | 2011-05-24 | 2019-01-28 | Zyngenia Inc | MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS |
FR2976811A1 (fr) | 2011-06-22 | 2012-12-28 | Lfb Biotechnologies | Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom |
JP2014534806A (ja) | 2011-08-23 | 2014-12-25 | ロシュ グリクアート アーゲー | 抗mcsp抗体 |
MY171038A (en) | 2011-08-23 | 2019-09-23 | Roche Glycart Ag | Bispecific antigen binding molecules |
EP2758435A1 (de) | 2011-09-23 | 2014-07-30 | Roche Glycart AG | Bispezifische anti-egfr-/anti-igf-1r-antikörper |
CN103890002A (zh) | 2011-10-19 | 2014-06-25 | 罗切格利卡特公司 | 岩藻糖基化抗体的分离方法 |
US20130302274A1 (en) | 2011-11-25 | 2013-11-14 | Roche Glycart Ag | Combination therapy |
US10117932B2 (en) | 2011-12-08 | 2018-11-06 | Biotest Ag | Uses of immunoconjugates targeting CD138 |
TWI593705B (zh) | 2011-12-28 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient |
WO2013113641A1 (en) | 2012-01-31 | 2013-08-08 | Roche Glycart Ag | Use of nkp46 as a predictive biomarker for cancer treatment with adcc- enhanced antibodies |
BR112014019579A2 (pt) | 2012-02-10 | 2019-10-15 | Genentech, Inc | Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero |
BR112014018374A8 (pt) | 2012-03-02 | 2017-07-11 | Roche Glycart Ag | Método para predizer a resposta d eum paciente com câncer, kit, anticorpo, método para o tratamento do câncer e composição farmacêutica |
JP6280031B2 (ja) | 2012-03-29 | 2018-02-14 | 中外製薬株式会社 | 抗lamp5抗体およびその利用 |
WO2013174927A1 (en) | 2012-05-23 | 2013-11-28 | Novartis International Pharmaceutical Limited | Production of fucosylated glycoproteins |
MX2014014162A (es) | 2012-05-24 | 2015-02-04 | Hoffmann La Roche | Anticuerpos multiespecificos. |
CN107964042B (zh) | 2012-05-30 | 2022-04-19 | 中外制药株式会社 | 靶组织特异性抗原结合分子 |
CA2871880A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
RU2015100656A (ru) | 2012-06-27 | 2016-08-20 | Ф. Хоффманн-Ля Рош Аг | Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения |
EP2874658A1 (de) * | 2012-07-18 | 2015-05-27 | Glycotope GmbH | Neue therapeutische behandlungen mit anti-her2-antikörpern mit geringer fucosylierung |
EP3434695B1 (de) | 2012-08-07 | 2020-12-02 | Roche Glycart AG | Verbesserte immuntherapie |
EP2912060B1 (de) | 2012-10-29 | 2019-12-25 | The University of North Carolina at Chapel Hill | Zusammensetzungen und verfahren zur hemmung von pathogenen infektionen |
EP2727942A1 (de) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Bispezifische Antikörper gegen menschliche EGFR, HER2 und HER3 |
EP2727943A1 (de) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Trispezifische Antikörper gegen menschliche EGFR, HER2 und HER3 |
EP2727941A1 (de) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Verfahren zur Herstellung multispezifischer Antikörper |
US20150259430A1 (en) | 2012-11-05 | 2015-09-17 | Mab Discovery Gmbh | Method for the production of multispecific antibodies |
EP3557260B1 (de) | 2012-12-21 | 2022-05-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3-gerichtetes arzneimittel, das einem patienten verabreicht wird, der auf die gpc3-gerichtete arzneimitteltherapie reagiert |
TWI693073B (zh) | 2012-12-21 | 2020-05-11 | 日商中外製藥股份有限公司 | 對gpc3標的治療劑療法為有效之患者投與的gpc3標的治療劑 |
US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
WO2014114595A1 (en) | 2013-01-23 | 2014-07-31 | Roche Glycart Ag | Predictive biomarker for cancer treatment with adcc-enhanced antibodies |
EP2953972B1 (de) | 2013-02-05 | 2020-07-08 | EngMab Sàrl | Verfahren zur auswahl von antikörpern gegen bcma |
EP2762496A1 (de) | 2013-02-05 | 2014-08-06 | EngMab AG | Verfahren zur Auswahl von Antikörpern gegen BCMA |
CA2896259A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Anti-mcsp antibodies |
MY185551A (en) | 2013-03-13 | 2021-05-19 | Genentech Inc | Antibody formulations |
UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
US20160159919A1 (en) | 2013-06-24 | 2016-06-09 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic Agent Comprising Humanized Anti-Epiregulin Antibody as Active Ingredient for Non-Small-Cell Lung Carcinoma Excluding Adenocarcinoma |
KR20160044060A (ko) | 2013-10-11 | 2016-04-22 | 에프. 호프만-라 로슈 아게 | 다중특이적 도메인 교환된 통상의 가변 경쇄 항체 |
WO2015082446A1 (en) | 2013-12-02 | 2015-06-11 | F. Hoffmann-La Roche Ag | Treatment of cancer using an anti-cdcp1 antibody and a taxane |
KR102284503B1 (ko) | 2013-12-04 | 2021-07-30 | 추가이 세이야쿠 가부시키가이샤 | 화합물의 농도에 따라 항원 결합능이 변화되는 항원 결합 분자 및 그의 라이브러리 |
BR112016013741A2 (pt) | 2013-12-17 | 2017-10-03 | Genentech Inc | Usos de antagonistas de ligação de eixo de pd-1 e um anticorpo de anti-cd20, e kit compreendendo os mesmos |
UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
AR100353A1 (es) | 2014-05-08 | 2016-09-28 | Chugai Pharmaceutical Co Ltd | Droga de direccionamiento a glipicano 3 (gpc3) que se administra a un paciente que responde a la terapia con drogas de direccionamiento a gpc3 |
JP7093612B2 (ja) * | 2014-05-27 | 2022-06-30 | アカデミア シニカ | Bacteroides由来のフコシダーゼおよびそれを使用する方法 |
PT3148581T (pt) | 2014-05-30 | 2020-01-06 | Henlix Biotech Co Ltd | Anticorpos antirrecetor do fator de crescimento epidérmico (egfr) |
CA2954974A1 (en) | 2014-07-21 | 2016-01-28 | Glykos Finland Oy | Production of glycoproteins with mammalian-like n-glycans in filamentous fungi |
AU2015318001B2 (en) | 2014-09-15 | 2021-03-25 | Genentech, Inc. | Antibody formulations |
PL3262071T3 (pl) | 2014-09-23 | 2020-08-10 | F. Hoffmann-La Roche Ag | Sposób stosowania immunokoniugatów anty-CD79b |
EP4141032A1 (de) | 2014-11-20 | 2023-03-01 | F. Hoffmann-La Roche AG | Kombinationstherapie von t-zell-aktivierenden bispezifischen antigenbindenden molekülen und pd-1-achsen-bindenden antagonisten |
PL3227332T3 (pl) | 2014-12-03 | 2020-06-15 | F. Hoffmann-La Roche Ag | Wielospecyficzne przeciwciała |
CA2984794A1 (en) | 2015-05-07 | 2016-11-10 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
EP3936524A3 (de) | 2015-05-11 | 2022-06-15 | F. Hoffmann-La Roche AG | Zusammensetzungen und verfahren zur behandlung von lupus nephritis |
EP3108897A1 (de) | 2015-06-24 | 2016-12-28 | F. Hoffmann-La Roche AG | Antikörper gegen menschliches csf-1r für die induzierung von lymphozytose in lymphomen oder leukämien |
EP3313887A2 (de) | 2015-06-26 | 2018-05-02 | MAB Discovery GmbH | Monoklonale anti-il1racp-antikörper |
JP2018520153A (ja) | 2015-06-29 | 2018-07-26 | ジェネンテック, インコーポレイテッド | 臓器移植における使用のためのii型抗cd20抗体 |
CA2992797A1 (en) | 2015-08-03 | 2017-02-09 | Engmab Sarl | Monoclonal antibodies against bcma |
US11254744B2 (en) | 2015-08-07 | 2022-02-22 | Imaginab, Inc. | Antigen binding constructs to target molecules |
MX2018003533A (es) | 2015-09-24 | 2019-04-25 | Abvitro Llc | Composiciones de anticuerpo de virus de inmunodeficiencia humana (vih) y metodos de uso. |
WO2017097723A2 (en) | 2015-12-09 | 2017-06-15 | F. Hoffmann-La Roche Ag | Treatment method |
WO2017148880A1 (en) | 2016-03-01 | 2017-09-08 | F. Hoffmann-La Roche Ag | Obinutuzumab variants having altered cell death induction |
EP3241845A1 (de) | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Humanisierte anti-il-1r3-antikörper |
WO2017194441A1 (en) | 2016-05-11 | 2017-11-16 | F. Hoffmann-La Roche Ag | Modified anti-tenascin antibodies and methods of use |
EP3252078A1 (de) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Typ ii anti-cd20 antikörper und anti-cd20/cd3 bispecific antikörper zur behandlung von krebs |
EP3257866A1 (de) | 2016-06-17 | 2017-12-20 | Academisch Medisch Centrum | Modifizierter anti-tnf-antikörper und verwendung davon bei der behandlung von entzündlicher darmerkrankung |
EP3535295A1 (de) | 2016-11-02 | 2019-09-11 | EngMab Sàrl | Bispezifische antikörper gegen bcma und cd3 und immunologisches arzneimittel zur kombinierten verwendung in der behandlung von multiplem myelom |
PE20190921A1 (es) | 2016-12-07 | 2019-06-26 | Agenus Inc | Anticuerpos y metodos de su utilizacion |
US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
WO2018184966A1 (en) | 2017-04-03 | 2018-10-11 | F. Hoffmann-La Roche Ag | Antibodies binding to steap-1 |
DK3606954T3 (en) | 2017-04-05 | 2022-09-26 | Hoffmann La Roche | Anti-LAG3-antistoffer |
CA3059468A1 (en) | 2017-04-27 | 2018-11-01 | Tesaro, Inc. | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof |
EP3401332A1 (de) | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antikörper zur verwendung bei entzündungskrankheiten |
JP2020521791A (ja) | 2017-06-02 | 2020-07-27 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | がんの治療のためのii型抗cd20抗体及び抗cd20/cd30二重特異性抗体 |
CN110869391A (zh) | 2017-07-26 | 2020-03-06 | 豪夫迈·罗氏有限公司 | 用BET抑制剂,Bcl-2抑制剂和抗CD20抗体的组合疗法 |
JP7437301B2 (ja) | 2017-08-25 | 2024-02-22 | ファイヴ プライム セラピューティクス インク | B7-h4抗体及びその使用方法 |
US11674125B2 (en) * | 2017-12-18 | 2023-06-13 | The General Hospital Corporation | Glycoengineering |
TWI805665B (zh) | 2017-12-21 | 2023-06-21 | 瑞士商赫孚孟拉羅股份公司 | 結合hla-a2/wt1之抗體 |
EP3731865A1 (de) | 2017-12-29 | 2020-11-04 | F. Hoffmann-La Roche AG | Verfahren zur verbesserung der vegf-rezeptor-blockierenden selektivität eines anti-vegf-antikörpers |
TWI829667B (zh) | 2018-02-09 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | 結合gprc5d之抗體 |
EP3755719A1 (de) | 2018-02-21 | 2020-12-30 | Five Prime Therapeutics, Inc. | B7-h4-antikörperdosierschemata |
CA3091174A1 (en) | 2018-02-21 | 2019-08-29 | Five Prime Therapeutics, Inc. | B7-h4 antibody formulations |
SG11202008105RA (en) | 2018-03-02 | 2020-09-29 | Five Prime Therapeutics Inc | B7-h4 antibodies and methods of use thereof |
EP3775184A1 (de) | 2018-03-29 | 2021-02-17 | F. Hoffmann-La Roche AG | Modulation der laktogenen aktivität bei säugerzellen |
CN112566938A (zh) | 2018-06-03 | 2021-03-26 | 拉姆卡普生物测试有限公司 | 针对ceacam5和cd47的双特异性抗体 |
AU2019343952A1 (en) | 2018-09-21 | 2021-04-22 | Mucommune, Llc | Synthetic binding agents for limiting permeation through mucus |
CA3114955A1 (en) | 2018-10-15 | 2020-04-23 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
KR20210100668A (ko) | 2018-12-06 | 2021-08-17 | 제넨테크, 인크. | 항-CD79b 면역접합체, 알킬화제 및 항-CD20 항체를 포함하는 미만성 큰 B-세포 림프종의 조합 요법 |
CN113621062A (zh) | 2018-12-21 | 2021-11-09 | 豪夫迈·罗氏有限公司 | 与cd3结合的抗体 |
US11130804B2 (en) | 2018-12-21 | 2021-09-28 | Hoffmann-La Roche Inc. | Antibody that binds to VEGF and IL-1beta and methods of use |
CN113613676A (zh) | 2019-03-19 | 2021-11-05 | 中外制药株式会社 | 包含对抗原的结合活性因mta而变化的抗原结合结构域的抗原结合分子及用于获得该抗原结合结构域的文库 |
KR20220007136A (ko) | 2019-05-14 | 2022-01-18 | 제넨테크, 인크. | 소포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법 |
AR119382A1 (es) | 2019-07-12 | 2021-12-15 | Hoffmann La Roche | Anticuerpos de pre-direccionamiento y métodos de uso |
AR119393A1 (es) | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | Anticuerpos que se unen a nkg2d |
EP4004045A1 (de) | 2019-07-31 | 2022-06-01 | F. Hoffmann-La Roche AG | An gprc5d bindende antikörper |
AU2020323686B2 (en) | 2019-07-31 | 2024-03-21 | F. Hoffmann-La Roche Ag | Antibodies binding to GPRC5D |
EP4028054A1 (de) | 2019-09-12 | 2022-07-20 | Genentech, Inc. | Zusammensetzungen und verfahren zur behandlung von lupus nephritis |
CN114423791A (zh) | 2019-09-18 | 2022-04-29 | 豪夫迈·罗氏有限公司 | 抗klk7抗体、抗klk5抗体、多特异性抗klk5/klk7抗体及使用方法 |
EP4045090A1 (de) | 2019-10-18 | 2022-08-24 | Genentech, Inc. | Verfahren zur verwendung von anti-cd79b-immunokonjugaten zur behandlung des diffusen grossen b-zelllymphoms |
EP3831849A1 (de) | 2019-12-02 | 2021-06-09 | LamKap Bio beta AG | Bispezifische antikörper gegen ceacam5 und cd47 |
EP4076666A1 (de) | 2019-12-18 | 2022-10-26 | F. Hoffmann-La Roche AG | An hla-a2/mage-a4 bindende antikörper |
CN115315446A (zh) | 2020-03-06 | 2022-11-08 | Go医疗股份有限公司 | 抗糖-cd44抗体及其用途 |
EP4127153A2 (de) | 2020-03-26 | 2023-02-08 | Genentech, Inc. | Modifizierte säugetierzellen mit reduzierten wirtszellproteinen |
KR20230005903A (ko) | 2020-04-24 | 2023-01-10 | 제넨테크, 인크. | 항-CD79b 면역접합체를 사용하는 방법 |
MX2022014422A (es) | 2020-05-17 | 2022-12-07 | Astrazeneca Uk Ltd | Anticuerpos contra el sars-cov-2 y metodos de seleccion y uso de los mismos. |
CN115697489A (zh) | 2020-06-08 | 2023-02-03 | 豪夫迈·罗氏有限公司 | 抗hbv抗体及其使用方法 |
MX2022016069A (es) | 2020-06-19 | 2023-02-02 | Hoffmann La Roche | Anticuerpos que se unen a cd3 y cd19. |
AR122656A1 (es) | 2020-06-19 | 2022-09-28 | Hoffmann La Roche | Anticuerpos que se unen a cd3 / folr1 |
PE20230835A1 (es) | 2020-06-19 | 2023-05-19 | Hoffmann La Roche | Anticuerpos que se unen a cd3 |
WO2021255146A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and cea |
WO2021262783A1 (en) | 2020-06-24 | 2021-12-30 | Genentech, Inc. | Apoptosis resistant cell lines |
PE20230434A1 (es) | 2020-07-10 | 2023-03-08 | Hoffmann La Roche | Anticuerpos que se unen a celulas cancerosas y dirigen radionucleotidos a dichas celulas |
CN116406377A (zh) | 2020-07-17 | 2023-07-07 | 基因泰克公司 | 抗notch2抗体及其使用方法 |
US20220041694A1 (en) | 2020-08-10 | 2022-02-10 | Astrazeneca Uk Limited | Sars-cov-2 antibodies for treatment and prevention of covid-19 |
CN116648507A (zh) | 2020-08-28 | 2023-08-25 | 基因泰克公司 | 宿主细胞蛋白的CRISPR/Cas9多重敲除 |
KR20230061458A (ko) | 2020-09-04 | 2023-05-08 | 에프. 호프만-라 로슈 아게 | Vegf-a 및 ang2에 결합하는 항체 및 사용 방법 |
JP2023545566A (ja) | 2020-10-20 | 2023-10-30 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Pd-1軸結合アンタゴニストとlrrk2阻害剤との併用療法 |
TW202233671A (zh) | 2020-10-20 | 2022-09-01 | 美商建南德克公司 | Peg結合抗mertk抗體及其使用方法 |
US20240082437A1 (en) | 2021-01-12 | 2024-03-14 | Hoffmann-La Roche Inc. | Split antibodies which bind to cancer cells and target radionuclides to said cells |
EP4277668A1 (de) | 2021-01-13 | 2023-11-22 | F. Hoffmann-La Roche AG | Kombinationstherapie |
EP4288458A1 (de) | 2021-02-03 | 2023-12-13 | Genentech, Inc. | Degraderplattform für multispezifische bindungsproteine und verfahren zur verwendung |
EP4301782A1 (de) | 2021-03-05 | 2024-01-10 | Go Therapeutics, Inc. | Anti-glyco-cd44-antikörper und deren verwendungen |
AR125074A1 (es) | 2021-03-12 | 2023-06-07 | Genentech Inc | Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso |
WO2022198192A1 (en) | 2021-03-15 | 2022-09-22 | Genentech, Inc. | Compositions and methods of treating lupus nephritis |
CA3215965A1 (en) | 2021-04-19 | 2022-10-27 | Amy Shen | Modified mammalian cells |
JP2024514281A (ja) | 2021-04-23 | 2024-04-01 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Nk細胞係合剤関連の有害作用の防止または軽減 |
TW202244059A (zh) | 2021-04-30 | 2022-11-16 | 瑞士商赫孚孟拉羅股份公司 | 用抗cd20/抗cd3雙特異性抗體進行治療之給藥 |
CA3213632A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
EP4337266A1 (de) | 2021-05-12 | 2024-03-20 | Genentech, Inc. | Verfahren zur verwendung von anti-cd79b-immunkonjugaten zur behandlung von diffusem grossem b-zell-lymphom |
WO2022246259A1 (en) | 2021-05-21 | 2022-11-24 | Genentech, Inc. | Modified cells for the production of a recombinant product of interest |
EP4351582A1 (de) | 2021-06-09 | 2024-04-17 | F. Hoffmann-La Roche AG | Kombination eines bestimmten braf-hemmers (paradoxbrecher) und eines pd-1-achsenbindenden antagonisten zur verwendung bei der behandlung von krebs |
WO2023288182A1 (en) | 2021-07-12 | 2023-01-19 | Genentech, Inc. | Structures for reducing antibody-lipase binding |
AU2022310847A1 (en) | 2021-07-14 | 2024-01-25 | Genentech, Inc. | Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use |
WO2023001884A1 (en) | 2021-07-22 | 2023-01-26 | F. Hoffmann-La Roche Ag | Heterodimeric fc domain antibodies |
CN117794953A (zh) | 2021-08-03 | 2024-03-29 | 豪夫迈·罗氏有限公司 | 双特异性抗体及使用方法 |
AU2022324456A1 (en) | 2021-08-05 | 2024-02-15 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
US20230099756A1 (en) | 2021-08-07 | 2023-03-30 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma |
CA3230934A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
CA3230933A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-lamp1 antibodies and their uses |
TW202342095A (zh) | 2021-11-05 | 2023-11-01 | 英商阿斯特捷利康英國股份有限公司 | 用於治療和預防covid—19之組成物 |
WO2023094569A1 (en) | 2021-11-26 | 2023-06-01 | F. Hoffmann-La Roche Ag | Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodies |
AR127887A1 (es) | 2021-12-10 | 2024-03-06 | Hoffmann La Roche | Anticuerpos que se unen a cd3 y plap |
US20230322958A1 (en) | 2022-01-19 | 2023-10-12 | Genentech, Inc. | Anti-Notch2 Antibodies and Conjugates and Methods of Use |
US20230414750A1 (en) | 2022-03-23 | 2023-12-28 | Hoffmann-La Roche Inc. | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
WO2023201299A1 (en) | 2022-04-13 | 2023-10-19 | Genentech, Inc. | Pharmaceutical compositions of therapeutic proteins and methods of use |
WO2023198727A1 (en) | 2022-04-13 | 2023-10-19 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use |
WO2023209177A1 (en) | 2022-04-29 | 2023-11-02 | Astrazeneca Uk Limited | Sars-cov-2 antibodies and methods of using the same |
WO2023217933A1 (en) | 2022-05-11 | 2023-11-16 | F. Hoffmann-La Roche Ag | Antibody that binds to vegf-a and il6 and methods of use |
WO2024077239A1 (en) | 2022-10-07 | 2024-04-11 | Genentech, Inc. | Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
EP1005870B1 (de) | 1992-11-13 | 2009-01-21 | Biogen Idec Inc. | Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierungs-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyten beschränkt ist, für die Behandlung von B-Zell-Lymphoma |
WO1996040210A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
US6180320B1 (en) | 1998-03-09 | 2001-01-30 | Mitsubishi Denki Kabushiki Kaisha | Method of manufacturing a semiconductor device having a fine pattern, and semiconductor device manufactured thereby |
ATE458007T1 (de) | 1998-04-20 | 2010-03-15 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
BR0014945A (pt) * | 1999-10-21 | 2004-08-31 | Monsanto Co | Modificação pós-traducional de proteìnas recombinantes produzidas em plantas |
CA2389217C (en) * | 1999-10-26 | 2016-12-06 | Plant Research International B.V. | Mammalian-type glycosylation in plants |
MXPA03000105A (es) | 2000-06-28 | 2004-09-13 | Glycofi Inc | Metodo para producir glicoproteinas modificadas. |
US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
WO2002079255A1 (en) * | 2001-04-02 | 2002-10-10 | Idec Pharmaceuticals Corporation | RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII |
NZ546945A (en) * | 2002-03-19 | 2008-04-30 | Plant Res Int Bv | A plant host cell system for the expression of human GnTIII |
PL224786B1 (pl) * | 2003-01-22 | 2017-01-31 | Glycart Biotechnology Ag | Wyizolowany kwas nukleinowy, ssaczy wektor ekspresyjny, komórki gospodarza, fuzja polipeptydowa i sposób jej wytwarzania, sposoby in vitro i ex vivo modyfikowania profilu glikozylacji polipeptydu wytwarzanego przez komórki gospodarza |
-
2004
- 2004-01-22 PL PL377967A patent/PL224786B1/pl unknown
- 2004-01-22 WO PCT/IB2004/000844 patent/WO2004065540A2/en active Application Filing
- 2004-01-22 CZ CZ2005490A patent/CZ308720B6/cs not_active IP Right Cessation
- 2004-01-22 SG SG2008049439A patent/SG179292A1/en unknown
- 2004-01-22 EP EP20100075272 patent/EP2264152B1/de not_active Expired - Lifetime
- 2004-01-22 DE DE602004028337T patent/DE602004028337D1/de not_active Expired - Lifetime
- 2004-01-22 ES ES10075273.2T patent/ES2542885T3/es not_active Expired - Lifetime
- 2004-01-22 NZ NZ603037A patent/NZ603037A/en not_active IP Right Cessation
- 2004-01-22 KR KR1020137008302A patent/KR101498588B1/ko active IP Right Grant
- 2004-01-22 NZ NZ567320A patent/NZ567320A/en not_active IP Right Cessation
- 2004-01-22 ES ES10075272.4T patent/ES2543734T3/es not_active Expired - Lifetime
- 2004-01-22 CA CA2513797A patent/CA2513797C/en not_active Expired - Lifetime
- 2004-01-22 PL PL393641A patent/PL222219B1/pl unknown
- 2004-01-22 PL PL415463A patent/PL224787B1/pl unknown
- 2004-01-22 PL PL393645A patent/PL222206B1/pl unknown
- 2004-01-22 EP EP10075271.6A patent/EP2264151B1/de not_active Expired - Lifetime
- 2004-01-22 PL PL393647A patent/PL222221B1/pl unknown
- 2004-01-22 MX MXPA05007781A patent/MXPA05007781A/es active IP Right Grant
- 2004-01-22 PL PL393644A patent/PL222220B1/pl unknown
- 2004-01-22 KR KR1020057013639A patent/KR101292000B1/ko active IP Right Grant
- 2004-01-22 AU AU2004205802A patent/AU2004205802B2/en not_active Expired
- 2004-01-22 NZ NZ541503A patent/NZ541503A/en not_active IP Right Cessation
- 2004-01-22 US US10/761,435 patent/US8367374B2/en active Active
- 2004-01-22 AT AT04704310T patent/ATE475708T1/de active
- 2004-01-22 EP EP04704310A patent/EP1587921B1/de not_active Expired - Lifetime
- 2004-01-22 CN CN201310218123.8A patent/CN103540600B/zh not_active Expired - Lifetime
- 2004-01-22 NZ NZ582315A patent/NZ582315A/en not_active IP Right Cessation
- 2004-01-22 JP JP2006500338A patent/JP5425365B2/ja not_active Expired - Lifetime
- 2004-01-22 PL PL393646A patent/PL222222B1/pl unknown
- 2004-01-22 EP EP20100075273 patent/EP2248892B1/de not_active Expired - Lifetime
- 2004-01-22 SG SG2013005590A patent/SG2013005590A/en unknown
- 2004-01-22 ES ES10075271.6T patent/ES2574993T3/es not_active Expired - Lifetime
- 2004-01-22 NZ NZ591970A patent/NZ591970A/xx not_active IP Right Cessation
-
2005
- 2005-07-21 IL IL169805A patent/IL169805A/en active IP Right Grant
- 2005-08-18 NO NO20053872A patent/NO339270B1/no not_active IP Right Cessation
-
2006
- 2006-08-25 HK HK06109471.3A patent/HK1089205A1/zh not_active IP Right Cessation
-
2010
- 2010-01-19 IL IL203402A patent/IL203402A/en active IP Right Grant
- 2010-02-04 AU AU2010200408A patent/AU2010200408C1/en not_active Expired
- 2010-06-09 JP JP2010132494A patent/JP2010233578A/ja not_active Withdrawn
-
2013
- 2013-02-05 US US13/759,925 patent/US8859234B2/en not_active Expired - Lifetime
- 2013-07-12 JP JP2013146287A patent/JP5953271B2/ja not_active Expired - Lifetime
-
2015
- 2015-04-24 JP JP2015089240A patent/JP2015142590A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE475708T1 (de) | Fusionskonstrukte und deren verwendung zur produktion von antikörpern mit erhöhter fc rezeptor bindungsaffinität und effektorfunktion | |
DE602005027093D1 (de) | Polypeptide mit lipase-aktivität und diese kodierende polynukleotide | |
DE602006019050D1 (de) | Polypeptide mit cellobiohydrolaseaktivität und dafür kodierende polynukleotide | |
EA200001023A1 (ru) | Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью | |
IL174794A0 (en) | Bispecific antibody substituting for functional proteins | |
DE60042969D1 (de) | Zubereitungen und methoden zur verwendung in rekombinatorischem klonen von nukleinsäuren | |
ATE521695T1 (de) | Zirkuläres dna-molekül mit einem konditionalen replikationsursprung, verfahren zur herstellung davon und ihre verwendung in der gentherapie | |
ATE515568T1 (de) | Polypeptide mit endoglucanase-aktivtät und dafür codierende polynukleotide | |
EA201171259A1 (ru) | Антительные гибридные белки с модифицированными сайтами связывания fcrn | |
ATE447013T1 (de) | Polypeptide mit endoglucanase-aktivtät und dafür codierende polynukleotide | |
WO2001029078A3 (en) | Method for production and use of mite group 1 proteins | |
Karfeld-Sulzer et al. | Fibrin hydrogel based bone substitute tethered with BMP-2 and BMP-2/7 heterodimers | |
WO2003008449A8 (en) | Ntb-a, a surface molecule involved in natural killer cells activity | |
DE60026733D1 (de) | Histone-deacetylase-8 proteine, nukleinsäuren und methoden zur verwendung | |
DE60139113D1 (de) | 18477, eine menschliche proteinkinase und deren verwendung | |
DE60238810D1 (de) | Rekombinante D-Hydantoin Hydrolasen und N-Carbamyl-Aminosäure Amid Hydrolasen, dafür kodierende DNA; deren Verwendung zur Herstellung von D-Aminosäuren | |
ATE236983T1 (de) | Durch zelldichte stimulierte protein-tyrosin- phosphatasen | |
ATE496133T1 (de) | Affinitätspolypeptid zur reinigung von rekombinanten proteinen | |
DE69932644D1 (de) | Menschliches Protein mit in vitro antiproliferativer Aktivität. | |
WO2001079525A3 (en) | Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same | |
WO2004029276A3 (en) | Nucleic acids encoding a mammalian raptor polypeptide and uses therefor | |
WO2005060479A3 (en) | Purified and isolated platelet calcium channel nucleic acids and polypeptides and therapeutic and screening methods using same | |
ATE411338T1 (de) | Nukleinsäuremolekül, umfassend eine für ein hämocyanin kodierende nukleinsäuresequenz und mindestens eine intronsequenz |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1587921 Country of ref document: EP |